Spectrum Pharmaceuticals Initiates Imitrex Patent Challenge

Spectrum Pharmaceuticals announced that it has initiated a challenge of the patent listed by GlaxoSmithKline in connection with GlaxoSmithKline's Imitrex injection 6mg/0.5mL. The exclusivity afforded the patent listed in the Orange Book for Imitrex injection expires on February 6, 2009. Spectrum's Abbreviated New Drug Application for sumatriptan succinate injection alleges that the Orange Book listed patent is invalid, unenforceable and/or would not be infringed by Spectrum's product.

Forbes (http://feeds.bignewsnetwork.com/redir.php?jid=996ee0a71aa1c0fa&cat=6dcd932030878143)